Takeda is a world-leading biopharmaceutical company based in Japan, guided by the values of Takedaism: Integrity, Justice, Honesty and Perseverance. These values live in our actions, which are taken based on and order of the algorithm Patient, Trust, Reputation, Business (PTRB).

We are in 80 countries, we have 31 factories and 3 research centers around the world, we are about 47,000 employees and TOP Employer in 38 countries.

Takeda in Portugal is TOP Employer for the third consecutive year in 2022 and focuses its efforts on Oncology, Gastroenterology, Rare Hematology & Plasma-Derived Therapies, Rare Genetic Diseases and Hereditary Angioedema. We also invest in R&D directed to Neurosciences and Vaccines.

Since 2009 in the country, at Takeda we have treated more than 1700 patients annually. We have about 50 employees. The company is in the TOP 10 of the national ranking of the pharmaceutical industry.

Takeda has 40 products in its clinical pipeline and of these, about 50% have the designation of orphans. We are leaders in rare diseases and specialized medicine, with the potential to launch 10 new orphan drugs in the next 5-7 years.

Of Takeda’s 240-year history, 80 have been linked to innovation in the field of rare diseases, both in immunology, hematology and gastroenterology, as well as in metabolic and lysosome diseases, in addition to aspiring to cure cancer with a focus also on certain types of low prevalence tumors.

The imperatives that guide Takeda are three: Patient, People and Planet.

At Takeda we aim to build a future where all people with diseases have research dedicated to enabling them a better future and access to the best innovation that allows them to have a better quality of life. And we know that this is only possible with partnerships and with the involvement and participation of all.

At Takeda we are committed to all projects and partnerships that contribute to finding the best solutions for patients, proposing necessary improvements to the health system and always in collaboration with all stakeholders.